NCT04017650View on ClinicalTrials.gov

Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

June 14, 2019

Primary Completion Date

December 30, 2025

Study Completion Date

December 30, 2025

Conditions
BRAF NP_004324.2:p.V600EMetastatic Colon AdenocarcinomaMetastatic Microsatellite Stable Colorectal CarcinomaMetastatic Rectal AdenocarcinomaProgressive DiseaseRecurrent Colorectal CarcinomaStage III Colorectal Cancer AJCC v8Stage IIIA Colorectal Cancer AJCC v8Stage IIIB Colorectal Cancer AJCC v8Stage IIIC Colorectal Cancer AJCC v8Stage IV Colorectal Cancer AJCC v8Stage IVA Colorectal Cancer AJCC v8Stage IVB Colorectal Cancer AJCC v8Stage IVC Colorectal Cancer AJCC v8Unresectable Colon AdenocarcinomaUnresectable Rectal Adenocarcinoma
Interventions
BIOLOGICAL

Cetuximab

Given IV

DRUG

Encorafenib

Given PO

BIOLOGICAL

Nivolumab

Given IV

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER